Encouragement design studies are particularly useful for estimating the effect of an intervention that cannot itself be randomly administered to some and not to others. They require a randomly selected group receive extra encouragement to undertake the treatment of interest, where the encouragement typically takes the form of additional information or incentives. We consider a "clustered encouragement design" (CED), where the randomization is at the level of the clusters (e.g. physicians), but the compliance with assignment is at the level of the units (e.g. patients) within clusters. Noncompliance and missing data are particular problems in encouragement design studies, where encouragement to take the treatment, rather than the treatment itself, is randomized. The motivating study looks at whether computer-based care suggestions can improve patient outcomes in veterans with chronic heart failure. Since physician adherence has been inadequate, the original study focused on methods to improve physician adherence, although an equally important question is whether physician adherence improves patient outcomes. Here, we reanalyze the data to determine the effect of physician adherence on patient outcomes. We propose causal inference methodology for the effect of a treatment versus a control in a randomized CED study with all-or-none compliance at the unit level. These methods extend the current approaches to account for nonignorable missing data and use an alternative approach to inference using multiple imputation methods, which have been successfully applied to a wide variety of missing data problems and have recently been applied to the potential outcomes framework of causal inference (Taylor and Zhou, 2009b) .
INTRODUCTION
For treatments that cannot be randomized, for ethical reasons or for lack of feasibility, it may be possible to randomize encouragement to the treatment of interest, which would increase use of treatment in the intervention arm while leaving the control arm treatment use unchanged. If the effect of encouragement is of interest, intention-to-treat (ITT) analyses are appropriate. But if interest lies in the effect of the treatment itself on outcome, then methods that focus on compliant subjects are more appropriate.
Our methods utilize a causal inference approach, referred to as principal stratification , which focuses on the potential outcomes among the subpopulation of compliers, who are not fully identifiable from the observed data. Alternative methods of modeling noncompliance, such as conditioning on the potential outcomes in selection models (Heitjan, 1999) or the use of structural equation models (Robins and others, 1999) , are not considered here. For research on nonignorable missing data methods and treatment noncompliance under the principal stratification framework, Frangakis and Rubin (1999) developed methods for encouragement designs using method of moments for inference; Taylor and Zhou (2009b) developed methods for this setting using a multiple imputation framework for inference. Barnard and others (1988) described methods that extend this template to allow for missing covariates and multivariate outcomes using a basic multiple imputations approach to inference, although they stopped short of implementing their methodology. Barnard and others (2003) later extended this framework to a more complicated form of crossover noncompliance (i.e. control patients could receive the intervention and intervention patients could receive the control) and used a Bayesian framework for inference. For research on encouragement design studies, Hirano and others (2000) developed methods for a binary outcome in a setting where outcomes are completely observed, relaxing the exclusion restrictions (often used to develop and identify estimands of interest) using a Bayesian framework for inference. Ten Have and others (2004) extended their approach to linear models for the continuous outcome. For research on CED studies, Frangakis and others (2002) developed methods in a setting where outcomes are completely observed, using a Bayesian framework for inference.
We propose to extend the methods of Frangakis and others (2002) for CED studies by incorporating nonignorable outcome nonresponse and by utilizing a multiple imputation approach to inference, which has been successfully applied to a wide variety of missing data problems, but has only recently been applied to the potential outcomes framework of causal inference. Taylor and Zhou (2009b) developed multiple imputation methods for the setting of crossover noncompliance and outcome nonresponse for a simple binary outcome without covariates or clustering and compared these methods to existing likelihood and moment methods. We extend these multiple imputation methods on binary outcome data to include clustering by physician and patient covariates and apply these methods to the guideline treatment study.
We begin with a description of the study that motivates our methods in Section 2. Section 3 defines the causal inference notation, assumptions, and parameters of interest. Section 4 defines the proposed models, and Section 5 describes the multiple imputation framework for inference. In Section 6, these methods are applied to data from a guideline treatment study previously studied by Subramanian and others (2004) .
MOTIVATIONAL STUDY
These methods are motivated by a study in veterans with chronic heart failure (Subramanian and others, 2004) . Chronic heart failure is a highly prevalent condition associated with serious morbidity, intense levels of health use, and shortened survival, where approximately two-thirds of patients die within 5 years of initial hospitalization (Ashton and others, 2000) . Veterans Affairs (VA) treatment guidelines in this population have been created to improve quality of health care, lessen clinical practice variation, and reduce costs (Audet and others, 1990; Institute of Medicine, 1992) . These guidelines consist of an algorithm that allows a clinician to follow a linear approach to evaluate and develop management strategies for the patient. These guideline rules are typically programmed into a locally developed decision support system and the workstations used by physicians.
The original study focused on methods to improve physician adherence through use of computer-based care suggestions, which involved sending the physician patient-specific electronic guideline treatment suggestions before each patient visit. Physicians were randomly assigned to receive either care suggestions generated with electronic medical data as well as symptom data obtained from questionnaires mailed to patients within 2 weeks of scheduled outpatient visits (intervention physicians) or care suggestions generated with electronic medical data alone (control physicians, where the control suggestions were considered a type of "standard of care" in these facilities). Since physician adherence had been inadequate, the original study focused on methods to improve physician adherence, although an equally important question is whether increased physician adherence improves patient outcomes. Under this study aim, which is the focus of this paper, physician-randomized intervention (e.g. physician encouragement to administer the guideline treatment) is a surrogate to induce the target treatment of interest (e.g. physician adherence), and thus there is a large amount of noncompliance.
POTENTIAL OUTCOMES FRAMEWORK
Causal inference, a growing area of statistical research, can be viewed as the extraction of information on the comparison between therapies or policies. An important and much-recognized statistical framework for causal inference is the one based on potential outcomes, which dates back to Neyman and Fisher (Neyman, 1923; Rubin, 1990) , and is often referred to as the Rubin Causal Model (Holland, 1986) . The approach to adjusting for noncompliance within this framework is a special case of the principal stratification framework defined by .
The role of time is important in this framework since variables are divided into two categories: pretreatment variables whose values are determined prior to treatment exposure and posttreatment variables whose values are determined after treatment exposure (Holland, 1986) . All posttreatment variables are potentially affected by the treatment or control. So for subject i, each posttreatment outcome variable Y i has two "potential outcomes": one under treatment, denoted Y i (1), and one under control, denoted Y i (0). We interpret Y i (1) as the value of the response that would have been observed if subject i were assigned the treatment, and Y i (0) as the value of the response that would have been observed on the same subject i if assigned control. It is impossible to observe both Y i (1) and Y i (0) since the subject is randomized to either treatment or control, but a statistical solution is found in working with average differences in potential outcomes across populations. In our research setting, posttreatment variables, for which potential outcomes will be specified, include physician adherence, patient outcomes, and response indicators.
Setting and notation
The setting consists of i = 1, . . . , N patients, where patient i has physician Q i for Q i = 1, . . . , M N . Then, Z i = 1 if patient i's physician is randomized to encouragement with medical records plus symptoms data, and 0 if patient i's physician is randomized to encouragement with medical records data alone. Since randomization is by physician cluster, Z i = Z j for Q i = Q j . Under the stable unit treatment value assumption (SUTVA), the potential physician adherence indicator D i (Z i ) = 1 if patient i's physician Q i adheres to guideline treatment under Z i , and D i (Z i ) = 0 otherwise.
Since patients had multiple visits over the 12 months of the study, we collapsed physician adherence to a binary variable, where a patient i's physician Q i is considered to have adhered if they provided guideline treatment at least once during the 12 months. We define guideline treatment to be treatment based on medical records and patient-specific symptom data. We have this data since both intervention and control suggestions were generated for all patients at all visits in the study; all future references to physician adherence will refer to this definition. Under SUTVA, we define Y i (Z i ) to be the binary potential outcome of interest, when patient i's physician is assigned Z i . In the guideline treatment study, Y i is a binary indicator of whether a patient's physical status improved over the 12 months of the study as measured by their New York Heart Association (NYHA) score. Let R i (Z i ) be the potential indicator for response, equal to 1 if Y i (Z i ) would be observed, and 0 if not, when patient i's physician is assigned Z i . Let X i be a vector of fully observed covariates for patient i. In the application, we adjust for baseline NYHA class since there were unequal numbers at baseline between treatment groups, where X i corresponds to binary indicators of baseline NYHA classes. There were no recorded physician-level covariates in the guideline treatment study. Table 1 provides a summary of all notation.
Assumptions
Our methods assume the SUTVA which states that a patient's treatment assignment does not affect other patients' outcomes. If we consider a physician with two patients, j and k, then SUTVA implies that how the physician treats patient j should not influence the outcome of patient k. In the application, the electronic reminders were sent prior to each patient visit and were patient specific (i.e. based on a specific patient's medical records, as well as, for intervention physicians, the patient's symptom information). So it is reasonable to expect the physician's responses to be specific to each patient, and independent of the physician's treatment of his or her other patients, which satisfies SUTVA. Although physician responses may be correlated within physician, which our methods take into account. The SUTVA then limits the number of potential outcomes by allowing us to write potential outcomes as functions of Z i rather than of the vector Z. We can then define the ITT causal effect of
In the guideline treatment study, if the patient's physician does not adhere when encouraged with medical data and patient-specific symptom data (i.e. the intervention), then we assume the patient's physician would not adhere when encouraged with medical data alone (i.e. the control). This is the "monotonicity assumption" (Imbens and Angrist, 1994) , which rules out the existence of defiers, making compliance type observable when
Unintentional missing data create problems since we are typically interested in making inference on the entire target population, not just the portion of the population that would provide responses. We choose a less restrictive assumption where we assume the missing data are nonignorable, which means that nonresponse is related in some partially unknown way to the missing data, even after adjusting for covariates known for responders and nonresponders. Specifically in our setting, missingness depends on latent compliance type (defined in Section 3.3), which is missing for patients where Z i = D i (under monotonicity); this assumption is called "latent ignorability" (Frangakis and Rubin, 1999) and formally, it assumes that within each latent principal compliance type as well as covariates and physician cluster, potential outcomes and associated potential response indicators are independent, or Pr[
We condition on covariates and physician clusters for two reasons: first, our methods and inference require conditioning on physician cluster since this is the level of the randomization and second, the assumption of ignorability is more plausible after conditioning on important covariates.
We do not assume any exclusion restrictions which hold that for certain subpopulations, treatment assignment does not affect outcomes or response behaviors. These restrictions would be violated if, for example, the electronic reminder prompts the physician to take measures beyond the suggested guidelines, like suggesting that the patient avoid unnecessary exposure to certain things. Without the exclusion restrictions, the parameters in Section 3.4 are "weakly identifiable" in the sense that there is no unique maximum likelihood (ML) estimator, although the posterior distribution is proper (Hirano and others, 2000) . Identification under Bayesian or multiple imputation methods is then based entirely on a carefully thought-out prior distribution.
Compliance principal strata
We then use the method of principal stratification , which divides the population into four compliance principal strata, as determined by the value of the vector of potential physician adherence indicators [D i 
Compliance type is not identified from the observable data on physician adherence D without additional assumptions. In particular, since patients are randomized to either the intervention or the control, we only observe D i (1) for patients assigned to the intervention, and D i (0) for patients assigned to the control. But there is some information on compliance type from the observed treatment assignment and physician adherence. For example, patients with physicians assigned the control arm where the physician was not guideline adherent (i.e. Z i = D i = 0) are a mixture of never-takers and compliers. Similarly, patients with physicians assigned to the intervention arm where the physician was adherent (i.e. Z i = D i = 1) are a mixture of always-takers and compliers. Note that conditioning on fully observed pretreatment covariates could substantially limit the extent of the relationship between D i (1) and D i (0) that is unobserved, depending on the strength of the covariates in predicting D i (1) and D i (0) (Zhang and Rubin, 2003; Rubin, 2004) . Principal strata have some important properties. First, they are not affected by assigned treatment, so we can adjust for them as we do for baseline covariates . Second, any comparisons made between potential outcomes within the principal strata are well-defined causal effects , allowing us to define estimands for the causal treatment effect that appropriately account for noncompliance.
Defining the causal estimands of interest
We define the ITT effect as ITT = t∈{n,a,c,d} 
, where ACE t is the average causal effect of randomized treatment Z on outcome Y for the subpopulation of compliance type t. Under monotonicity, defiers do not exist, and the never-takers and always-takers, by definition of these groups, do not carry information about the comparison between treatments with respect to finding the causal effect of treatment on outcome (Sommer and Zeger, 1991; Sheiner and Rubin, 1995) . Therefore, we focus on the the subpopulation of compliers and define the complier average causal effect (CACE) to be
, which is the average treatment effect among the subpopulation of compliers. In the application, the CACE is the comparison of randomized groups on patient NYHA improvement among patients whose physician would adhere when assigned the intervention and would not adhere when assigned the control. Put simply, the CACE is the as-treated effect of physician adherence on patient NYHA improvement.
PARAMETRIC MODELS
Since randomization is at the level of the physician, randomized assignment is ignorable only after conditioning on physician cluster. Therefore, any inference on potential outcomes must condition on physician cluster which may lessen the precision since no physician has patients in both arms (Frangakis and others, 2002) . Under latent ignorability, we model the joint distribution of
We model the compliance principal strata as a multinomial logit model, or Pr(
qa ), and t ∈ {n, c, a},
.
We set {ψ n0 , ψ n1 , ψ n2 , ψ n3 } ≡ (0, 0, 0, 0), as well as b
qn ≡ 0 for q = 1, . . . , M, to normalize the probabilities. Here, {ψ c0 , ψ c1 , ψ c2 , ψ c3 } and {ψ a0 , ψ a1 , ψ a2 , ψ a3 } model the association between compliance principal strata and covariates, and b (C) q model the association between compliance principal strata and physician cluster.
We model the binary potential outcomes as logistic regressions or Pr
We let η t01 = η t11 ≡ η 0.1 , η t02 = η t12 ≡ η 0.2 , and η t03 = η t13 ≡ η 0.3 for t ∈ {n, c, a}, which reduces the number of parameters. Although it does not complicate the methodology to allow separate coefficients, we did not have a strong a priori belief that the baseline covariate's effect on potential outcomes would vary by compliance type or treatment assignment. Given the sample size in this study, this should help increase precision in the estimates of interest.
We model the binary potential outcome responses as logistic regressions, or Pr[
q ) where, for γ t z ≡ {γ t z1 , γ t z2 , γ t z3 },
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Similar to the outcome model parameters, we let γ t01 = γ t11 ≡ γ 0.1 , γ t02 = γ t12 ≡ γ 0.2 , and γ t03 = γ t13 ≡ γ 0.3 for t ∈ {n, c, a}.
Likelihood
We define the vector of all parameters to be θ . Let ζ (t) be the subset of patients with complier type t, and let δ(z, d) be the subset of patients with observed (Z i = z, D i = d). The observed likelihood takes a complicated form and is defined in Section 1 of the supplementary material available at Biostatistics online. However, the likelihood based on the complete data {C,Z,D,Y,R,X,Q} takes a much simpler form, where
Since the complete data likelihood is easier to work with than the observed data likelihood, we can utilize missing data methods such as the Gibbs sampler (Geman and Geman, 1984) .
Prior selection
We perform two separate analyses using two types of priors that are computationally tractable for this application. For the first type, we use a prior distribution that is proper but diffuse in order to be relatively uninformative for our application. Given the physician-specific parameters, we posit the following independent prior distributions:
independently across physicians q = 1, . . . , M. I is the identity matrix and ξ is the inflation factor that we set. We assume that the inverse of V b has a Wishart distribution with scale matrix (α R) −1 with α = 10 degrees of freedom.
For the second prior, since the observed likelihood involves a mixture over a large amount of missing data, we use a prior with conjugate form. This more informative prior can be fit using the same model but adding artificial patients to the data set (Hirano and others, 2000) . Prior information is expressed by attaching weights to the artificial patients' contribution to the likelihood, where weights are based on the combinations of cluster indicators, covariates, compliance groups, randomized assignment, outcomes, and observed response indicators. We use a prior that corresponds to adding 30 observations to the likelihood. This corresponds to 10 additional observation for each compliance type, where the 10 observations are then split into 10/(32Q) observations for each of the 32Q combinations of
Formally, the prior distribution is as follows:
where MVN(0, V b ) is the multivariate normal distribution for b q with mean vector 0 and variance V b , and InvWis is the inverse Wishart distribution we assume for the distribution of V b , with hyperparameters (α R) −1 and α for the scale matrix and degrees of freedom, where, for the scale matrix, we use an approximation of V b based on the posterior distribution under the uninformative prior distribution described above, with α = 10.
FRAMEWORK FOR MULTIPLE IMPUTATION
In the principal stratification framework, existing methods for estimation of the treatment effect include Bayesian (Imbens and Rubin, 1997; Hirano and others, 2000; others, 2002), likelihood (O'Malley and Normand, 2005; Zhou and Li, 2005) , and moment methods (Frangakis and Rubin, 1999; Levy and others, 2004; O'Malley and Normand, 2005; Taylor and Zhou, 2009a ). An interesting alternative is multiple imputation (Rubin, 1987) , a method that has been successfully applied to a wide variety of missing data problems but has only recently been applied to the potential outcomes setting of causal inference (Taylor and Zhou, 2009b) . Taylor and Zhou (2009b) provide a detailed list of the advantages of multiple imputation (MI) in this causal inference setting, which include the fact that neither the monotonicity nor the compound exclusion restrictions, which have been used to develop and justify estimation procedures under ML and moment methods, are essential for the MI analysis, and violations of these assumptions can be addressed. In addition, MI can be used in virtually any setting, whereas ML is much more restricted in its applications, requiring specially designed expectation-maximization algorithms and difficult analytic or numerical integration on the log likelihood for intervals.
If we partition the complete data M into the observed data, M obs = (Y obs , Z , D, R, X, Q), and the missing data, M mis = (Y mis , C mis ), we then draw from the joint distribution P(M mis , θ |M obs ) ≡ P(Y mis , C mis , θ |Y obs , Z , D, R, X, Q) by recursively iterating between the draws from P(Y mis |C mis , Y obs , Z , D, R, X, Q, θ), P(C mis |Y obs , Z , D, R, X, Q, θ), and P(θ |Y obs , Z , D, R, X, Q). We use a Gibbs sampler (Geman and Geman, 1984) and a Metropolis-Hastings algorithm (Metropolis and others, 1953; Hastings, 1970) for computation of all reported results, where the details are described in Section 2 of the supplementary material available at Biostatistics online.
For our setting, if the percent of missing information was even as high as 90%, then an estimate based on m = 10 imputations would tend to have a standard error only 1.04 times as large as the estimate with m = ∞ imputations; therefore 10 imputations is adequate for our setting. The next step, or the analysis stage, involves calculating the complete data estimates of the estimands of interest using complete data methods.
Since we are interested in the marginal mean, but would like to use likelihood-based methods at the analysis stage (which were also used in the imputation stage), we chose a marginalized random effect model (Heagerty and Zeger, 2000) , which uses a conditional approach but averages over random effects. This approach embraces the interpretation and robustness of regression coefficients from the marginal model while retaining the likelihood inference capabilities and flexible dependence specifications from a random effects model (Griswold and Zeger, 2004) . This model can be implemented in existing software (like SAS) by formulating the marginal models through conditional specifications, which facilitate estimation with computation solutions already in place (Griswold and Zeger, 2004) . See Section 3 of the supplementary materials section available at Biostatistics online for a more detailed description of the marginalized random effects models used at the analysis stage.
For each complete data set, we obtain parameter estimates for the CACE and compliance type, (Q 1 , Q 2 , . . . ,Q m ), along with their approximate variances, (U 1 , U 2 , . . . , U m ), based on the second derivative matrix of the likelihood function. Similar methods are used to obtain estimates for all estimands of interest. We then combine results from the completed data sets using the rules defined in Rubin (1987) .
APPLICATION TO THE GUIDELINE TREATMENT STUDY
The study was done among primary care physicians caring for outpatients with heart failure at two VA medical centers. Although subjects were not eligible to participate in the original study if their physicians did not expect them to survive 1 year (Subramanian and others, 2004) , death data were not included in this analysis. Since outcomes for patients who die are, by definition, nonexistent, it is a limitation of this analysis that outcomes may have been imputed for patients who died during the 12 months of the study. A discussion of how to adjust for censoring due to death using the principal stratification framework can be found in Zhang and Rubin (2003) and Rubin (2006) . Table 2 provides patient characteristics and baseline information, where 38% of patients under the control (Z i = 0) had NYHA improvement over the 12 months of the study, and 45% of patients whose physician was assigned the intervention had improvement. A substantial number of veterans with heart failure were not receiving care in accordance with accepted local guidelines. Overall, less than half the 112 (66) 141 (73) 253 (70) patients received guideline treatment at least once during the 12 months of this study. Approximately half the patients, whose physicians were assigned the intervention, did not receive guideline treatment; these patient-physician pairs must be never-takers (or, more descriptively, "never-guideline-treatmentreceivers"); similarly there were 36% of patient-physician pairs in the control arm who must be alwaystakers (or "always-guideline-treatment-receivers"). The remaining patient-physician pairs in the control arm were either compliers or never-takers, and those remaining in the intervention arm were either compliers or always-takers.
For an initial examination of the data, we used the multiple imputation methods developed in Taylor and Zhou (2009b) on binary outcomes without covariates or clustering using M = 10 imputations. Results are reported in the first column of Table 3 , where there was an estimated 12% (95% CI: −67.6, 92.1) NYHA improvement among the complier subpopulation. The results from adjusting for covariates are reported in the latter two columns of Table 3 , corresponding to the two different priors used in the two analyses. We adjusted for baseline NYHA status (with three indicator variables for status II, III, and IV) since this was somewhat unbalanced at baseline, with patients in the intervention arm worse off (i.e. having higher NYHA scores at baseline) than control patients (Table 2) .
Under the conjugate prior that adds 30 artificial patients to the likelihood, guideline treatment produced an estimated 4% (95% CI: −25.2, 32.2) improvement in NYHA status, where including covariates substantially lowered variability in the estimated treatment effect. Similar nonsignificant effects were found in the never-taker and always-taker subpopulations (.1% [95% CI: −11.3, 11.5]; 1.9% [95% CI: −11.9, 15.6], respectively). Similar results were found under the noninformative prior where the slightly negative treatment effect among the compliers had a wide confidence interval which included zero, making the negative result consistent with random fluctuation. The last six rows of Table 3 report results on response indicators for all models, where overall rates of outcome response were lowest among compliers and highest among always-takers. Table 4 reports the estimated proportion within each compliance subpopulation by covariates. Overall, under the conjugate prior, 13% of the patient-physician pairs were compliers, 50% were never-takers (where a high proportion of never-takers was expected since guideline-treatment adherence is a known problem for physicians in this patient population), and 37% were always-takers. Similar results were found under the noninformative prior. Patients with higher NYHA baseline scores (where high scores are worse for the patient) tended to have slightly lower proportions of compliers and higher proportions of never-takers than patient with higher baseline NYHA scores. In order to assess sensitivity of inference to the parameters in our priors, Table 5 displays results based on three different inflation factors (ξ = 5, 3, and 0.5) under the normal priors, and three different numbers of pseudo subjects (PS) under the conjugate prior (PS = 9, 15, and 45). Inferences are similar both in the estimated treatment effect among compliance subpopulations and in the estimated proportions within each compliance subpopulation.
Since there was no significant improvement in NYHA status over the course of the study for the compliers, our results suggest that physician adherence to treatment guidelines in this setting does not necessarily improve patient outcomes. This implies a need for further research on management strategies for veterans with heart failure in order to provide them optimal care.
DISCUSSION
We developed methodology for cluster-randomized studies with individual-level noncompliance. The proposed methods improve upon current procedures for the clustered encouragement design by incorporating nonignorable missing data and by utilizing an alternative approach to inference using a multiple imputation framework which has potential advantages over existing methods of inference.
Future work could focus on continuous outcomes and incorporate additional physician adherence categories since, to make the observed data in the guideline treatment study conform to our template, we had to reduce the physician adherence variables at multiple visits to a single indicator of physician adherence, thereby losing information. Others have incorporated principal strata based on multilevel posttreatment variables using principal stratification methods (Mattei and Mealli, 2007) . Future work could also use direct marginal modeling for the analysis stage of the multiple imputation inference and could also address the frequentist properties (e.g. finite sample behavior) of the multiple imputation estimator in the CED setting, varying the number of clusters and cluster size, as well as estimator behavior under misspecified models and assumptions.
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